Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?

Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection

(2011) Stefan Zeuzem et al.   GASTROENTEROLOGY

Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment Failure

(2011) Jonathan Z. Li   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir

(2011) Simone Susser et al.   JOURNAL OF CLINICAL VIROLOGY

1242 LONG-TERM FOLLOW-UP OF CHRONIC HEPATITIS C INFECTED PATIENTS TREATED WITH TELAPREVIR: EVALUATION OF PERSISTENCE OF RESISTANT VARIANTS BY ULTRA-DEEP SEQUENCING

(2011) X.V. Thomas et al.   JOURNAL OF HEPATOLOGY

67 MOLECULAR CHARACTERIZATION OF HCV RESISTANCE TO TELAPREVIR BY MEANS OF ULTRA-DEEP PYROSEQUENCING: PREEXISTING RESISTANT VARIANTS AND DYNAMICS OF RESISTANT POPULATIONS

(2011) S. Chevaliez et al.   JOURNAL OF HEPATOLOGY

1202 CHARACTERISATION OF HCV VARIANTS IN NON-SVR PATIENTS IN THE REALIZE STUDY SUGGESTS THAT TELAPREVIR EXHIBITS A CONSISTENT RESISTANCE PROFILE IRRESPECTIVE OF A LEAD-IN

(2011) S. De Meyer et al.   JOURNAL OF HEPATOLOGY

8 EVOLUTION OF TREATMENT-EMERGENT RESISTANT VARIANTS IN TELAPREVIR PHASE 3 CLINICAL TRIALS

(2011) J.C. Sullivan et al.   JOURNAL OF HEPATOLOGY

Hepatitis C virus resistance to protease inhibitors

(2011) Philippe Halfon et al.   JOURNAL OF HEPATOLOGY

New direct-acting antivirals' combination for the treatment of chronic hepatitis C

(2011) Tarik Asselah et al.   LIVER INTERNATIONAL

A diverse range of gene products are effectors of the type I interferon antiviral response

(2011) John W. Schoggins et al.   NATURE

Antiviral resistance and hepatitis B therapy

(2010) Marc G. Ghany et al.   HEPATOLOGY

2016 LONG-TERM OUTCOMES FOLLOWING COMBINATION TREATMENT WITH BOCEPREVIR PLUS PEG-INTRON/RIBAVIRIN (P/R) IN PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPE 1 (CHC-G1)

(2010) J.M. Vierling et al.   JOURNAL OF HEPATOLOGY

Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms

(2010) Wolf Peter Hofmann et al.   LIVER INTERNATIONAL

Telaprevir for Previously Treated Chronic HCV Infection

(2010) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hepatitis C Virus Compartmentalization and Infection Recurrence after Liver Transplantation

(2009) S. Ramirez et al.   AMERICAN JOURNAL OF TRANSPLANTATION

GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796

(2009) M. F. McCown et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients

(2009) Henk W. Reesink et al.   GASTROENTEROLOGY

Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection

(2009) Christoph Sarrazin et al.   GASTROENTEROLOGY

Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients

(2009) Simone Susser et al.   HEPATOLOGY

Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection

(2009) Christophe Hézode et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

(2008) M. F. McCown et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Gene expression and hepatitis C virus infection

(2008) T Asselah et al.   GUT

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

(2008) Thomas Kuntzen et al.   HEPATOLOGY

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

(2008) S. Palmer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA